Dr. Roger Li, MD

Dr. Li practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Li's NPI, 1841515525, was assigned on April 6, 2010. Dr. Li graduated from UC Irvine School of Medicine in 2010. Dr. Li's Texas license number on file is Q9416.

Dr. Li's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Li's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Li is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Li to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Li practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Li's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Li is board certified in urology by the American Board of Urology. Dmand AI has Dr. Li's licenses on file in 3 states: Texas, Florida and California.

Dmand AI lists bladder removal, kidney removal surgery, prostate surgery, urinary endoscopy and urine flow blockage among the conditions Dr. Li treats.

CMS data shows 381 Medicare services from Dr. Li across 6 procedure codes in 2024, for 215 Medicare patients. Medicare paid $28,119 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 215 Medicare patients who saw Dr. Li in 2024. The largest group is 75 to 84, with 95 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Li's median patient age at 74, with 19% women.

In 2024, Dr. Li wrote 100 Medicare Part D claims for 65 patients. 99% of them were for generic drugs. CMS names the drug for 65 of them, across 2 drugs with 11 or more claims each, at $676 in total drug cost. In 2023, CMS named 110 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Li for performance year 2024, reported as part of a group. Dr. Li accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Li as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 136 papers to Dr. Li, published from 2004 to 2025. 2024 was the busiest year, with 19. The most frequent topics are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell and Cystectomy. Dr. Li has published most often in Eur Urol. Dr. Li's most frequent co-authors are Philippe E. Spiess, MD, Scott Michael Gilbert, MD and Ashish M. Kamat, MD.

Dmand AI links Dr. Li to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms and Urinary Bladder Diseases.

CMS Open Payments shows 76 general payments to Dr. Li from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Ferring Pharmaceuticals Inc. paid the most, $11,001. It also lists 1 research payment totaling $780 in 2025.

Dmand AI lists 9 awards for Dr. Li, most recently Junior Faculty Research Award in 2022.

Dr. Li graduated from UC Irvine School of Medicine in 2010.

Dr. Li is in network with 9 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.